Aggrenox (Boehringer Ingelheim/GlaxoSmithKline/Bayer) capsules contain two active ingredients, acetylsalicylic acid and extend-release dipyridamole. Each active ingredient inhibits platelet aggregation through a distinct pathway. Aspirin works by irreversibly inhibiting the cyclooxygenase-1 and cyclooxygenase-2 enzymes, which are responsible for the synthesis of prostaglandins and thromboxanes. Prostaglandins and thromboxanes trigger the platelet aggregation needed for clot formation to occur. By inhibiting cyclooxygenase-1 and cyclooxygenase-2, Aspirin decreases the number of prostaglandins and thromboxanes present, resulting in a reduction in platelet aggregation. By limiting platelet aggregation, Aspirin inhibits blood clot formation.
LIST OF FIGURES
9 Figure 1: Aggrenox for ischemic stroke – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Aggrenox for ischemic stroke
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Aggrenox for ischemic stroke
LIST OF TABLES
6 Table 1: Aggrenox drug profile
7 Table 2: Aggrenox pivotal trial data in ischemic stroke
8 Table 3: Aggrenox late-phase trial data in ischemic stroke
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.